Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle,…
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs.
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.
Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Rallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday’s after-market session. The company’s market cap stands at…
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
(VERA) – Analyzing Vera Therapeutics’s Short Interest
Vera Therapeutics’s (NYSE:VERA) short percent of float has fallen 3.75% since its last report. The company recently reported…
Analyst Highlights ‘Rock Solid’ Data For Vera Therapeutics’ Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.
What’s Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.